FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5042-5047

  Zimbeck, Alicia J ^a   Iqbal, Naureen ^a   Ahlquist, Angela M ^a,b   Farley, Monica M ^c,d   Harrison, Lee H ^e   Chiller, Tom ^a   Lockhart, Shawn R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; GLUCAN SYNTHASE; MICAFUNGIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CANDIDEMIA; FKS1 GENE; FKS2 GENE; FUNGAL GENE; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION;

EID: 78649671319     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00836-10     Document Type: Article

References (38)

1. Ahlquist, A., M. M. Farley, L. H. Harrison, W. Baughman, B. Siegel, R. Hollick, S. R. Lockhart, S. S. Magill, and T. Chiller. 2009. Epidemiology of candidemia in metropolitan Atlanta and Baltimore city and county: preliminary results of population-based, active laboratory surveillance - 2008-2010, abstr. M-1241. Abstr. 49th Int. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC.
2. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
3. Bennett, J. E. 2006. Echinocandins for candidemia in adults without neutropenia. N. Engl. J. Med. 355:1154-1159.
4. Cappelletty, D., and K. Eiselstein-McKitrick. 2007. The echinocandins. Pharmacotherapy 27:369-388.
5. Castanheira, M., L. N. Woosley, D. J. Diekema, S. A. Messer, R. N. Jones, and M. A. Pfaller. 2010. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
6. Chandrasekar, P. H., and J. D. Sobel. 2006. Micafungin: a new echinocandin. Clin. Infect. Dis. 42:1171-1178.
7. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
8. Clinical Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed. Clinical Laboratory Standards Institute, Wayne, PA.
9. Deak, E., K. A. Etienne, S. R. Lockhart, L. Gade, T. Chiller, and S. A. Balajee. 2010. Utility of a Luminex-based assay for multiplexed, rapid species identification of Candida isolates from an ongoing candidemia surveillance. Can. J. Microbiol. 56:348-351.
10. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
11. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, E. Dannaoui, and the European Committee on Antibiotic Susceptibility Testing. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
12. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
13. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
14. Garcia-Effron, G., D. J. Chua, J. R. Tomada, J. Dipersio, D. S. Perlin, M. Ghannoum, and H. Bonilla. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
15. Garcia-Effron, G., S. Lee, S. Park, J. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
16. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
17. Kartsonis, N., J. Killar, L. Mixson, C. M. Hoe, C. Sable, K. Bartizal, and M. Motyl. 2005. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. 49:3616-3623.
18. Katiyar, S., M. A. Pfaller, and T. D. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
19. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
20. Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, H. McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J. Gibson, and D. G. Higgins. 2007. ClustalW and ClustalX version 2. Bioinformatics 23:2947-2948.
21. Laverdière, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
22. Lott, T. J., J. P. Frade, and S. R. Lockhart. 2010. Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eukaryot. Cell 9:619-625.
23. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.
24. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
25. Park, S., R. Kelly, N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
26. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
27. Pfaller, M. A. 2004. Anidulafungin: an echinocandin antifungal. Expert Opin. Invest. Drugs 13:1183-1197.
28. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, R. N. Jones, J. Turnidge, and D. J. Diekema. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
29. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
30. Pfaller, M. A., D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and B. P. Goldstein. 2005. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49:4795-4797.
31. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
32. Pfaller, M. A., S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, J. Kroeger, and D. J. Diekema. 2009. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J. Clin. Microbiol. 47:3185-3190.
33. Pond, S. L., S. D. Frost, and S. V. Muse. 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21:676-679.
34. Sun, H. Y., and N. Singh. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 35:211-218.
35. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
36. Thompson, G. R., N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis, and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
37. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
38. Zaas, A. K., and B. D. Alexander. 2005. Echinocandins: role in antifungal therapy, 2005. Expert Opin. Pharmacother. 6:1657-1668.